



Oncomine™ Myeloid Research Assay Gene List

Fusion Driver Genes (29)			Hotspot Genes (23)		Full Genes (17)		Expression Genes (5)	Expression Control Genes (5)
ABL1	HMGA2	NUP214	ABL1	KRAS	ASXL1	PRPF8	BAALC	EIF2B1
ALK	JAK2	PDGFRA	BRAF	MPL	BCOR	RB1	MECOM	FBXW2
BCL2	KMT2A (MLL)	PDGFRB	CBL	MYD88	CALR	RUNX1	MYC	PSMB2
BRAF	RARA	RARA	CSF3R	NPM1	CEBPA	SH2B3	SMC1A	PUM1
CCND1	MECOM	RBM15	DNMT3A	NRAS	ETV6	STAG2	WT1	TRIM27
CREBBP	MET	RUNX1	FLT3	PTPN11	EZH2	TET2		
EGFR	MLLT10	TCF3	GATA2	SETBP1	IKZF1	TP53		
ETV6	MLLT3	TFE3	HRAS	SF3B1	NF1	ZRSR2		
FGFR1	MYBL1		IDH1	SRSF2	PHF6			
FGFR2	MYH11		IDH2	U2AF1				
FUS	NTRK3		JAK2	WT1				
			KIT					

Contact us to learn how Biodesix can support your program: bizdev@biodesix.com

About Biodesix

Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ and EarlyCDT Lung® nodule tests, evaluate the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.